Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01957007 · ClinicalTrials.gov registry record · Phase 1

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

A Phase 1 study of Solid Tumors, sponsored by OncoMed Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
34
Enrollment target
3
Study locations

NCT01957007 is a Phase 1 study of Solid Tumors that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 34 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01957007, a Phase 1 study of Solid Tumors, has completed, sponsored by OncoMed Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
34 participants
Enrollment target
3
Study locations

Study Summary

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with docetaxel.

Conditions Studied

Solid Tumors

Interventions

  • DRUG Docetaxel
  • DRUG vantictumab

Study Locations (3)

Colorado

  • University of Colorado - Aurora

New York

  • Roswell Park Cancer Center, Elm & Carlton Streets - Buffalo

Ohio

  • Case Western Reserve University - Cleveland

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2013-09
Est. Completion 2017-06
Phase Phase 1

Sponsor

OncoMed Pharmaceuticals

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01957007

The ClinicalTrials.gov registry entry for NCT01957007 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (88% lower). The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.

NCT01957007 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT01957007 about?

NCT01957007 is a clinical study titled "A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC". This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with docetaxel.

What is the current status of trial NCT01957007?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2013-09. Estimated completion is 2017-06.

What conditions does trial NCT01957007 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT01957007?

The interventions under investigation include: Docetaxel (DRUG), vantictumab (DRUG).

Who is sponsoring clinical trial NCT01957007?

This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01957007 being conducted?

This trial has 3 study locations across Colorado, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.